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OBJECTIVES: This study compared the effectiveness of rosuv-
astatin (RSV) to other statins prescribed in clinical practice in
prevention of fatal and non-fatal cardiovascular (CV) events.
METHODS: This longitudinal inception cohort study, conducted
using MedStat MarketScan research databases, included patients
aged 18 who started statin therapy during August 2003 to
December 2005. Patients were followed until 90 days after index
statin monotherapy exposure, an event, end of eligibility, or end
of study. The primary endpoint was a composite of CV death
(in-hospital only), myocardial infarction, unstable angina, coro-
nary revascularization, stroke, and carotid revascularization.
Adjusted time-to-event analyses incorporating a propensity score
covariate were used, and analyses were stratiﬁed by duration of
statin exposure. RESULTS: Among 395,039 patients who met
inclusion/exclusion criteria, 12% initiated rosuvastatin (RSV),
and 9,622 (2.4%) experienced an outcome event (3.7 per 100
person-years). The median (mean) duration of statin treatment
and follow-up was 100 (180) days and 180 (242) days, respec-
tively. Although no statistically signiﬁcant difference in CV
event rates between RSV and other statins was observed after
adjustment for demographics and medical/prescription history
(HR = 0.99, 95% CI = 0.93–1.06), a trend toward increased
beneﬁt was seen with longer exposure time with RSV compared
to “other statins” (90 days exposure, HR = 0.97, 95%
CI = 0.86–1.09; 180 days, HR = 0.91, 95% CI = 0.78–1.06;
270 days, HR = 0.80, 95% CI = 0.64–1.00; 360 days,
HR = 0.88, 95% CI = 0.65–1.19). Other study end-points, strati-
ﬁcations, and comparisons with speciﬁc statin drugs were evalu-
ated. CONCLUSION: Primary analysis showed similar incidence
rates of CV-related events in a clinical practice setting between
the statin cohorts over a median of 180 days of follow-up. With
longer exposure times, a trend of a decreased CV event rate with
RSV as compared to other statins was found. These ﬁndings are
consistent with a beneﬁcial effect of aggressive LDL lowering
treatment in a clinical practice setting.
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OBJECTIVES: The increasing number of clinical trials in hyper-
tension provides data to inform more effective treatment strate-
gies, but partly generate contradicting results. Synthesis of
individual trial data using meta-analytic techniques ensures more
reliable estimates on treatment outcomes. To compare the anti-
hypertensive efﬁcacy of telmisartan 40 and 80 mg, against all
other available drugs in this class (AIIA) by undertaking a meta-
analysis of individual randomised controlled trials. METHODS:
Two distinct approaches were followed. Direct comparison of the
efﬁcacy of telmisartan versus other AIIA therapies using evidence
from studies performed head to head, and indirect comparison
using placebo as common comparator. Fixed and random effects
meta-analyses were conducted for all comparisons. The studies
used reported trough measurements. RESULTS: Direct compari-
sons of telmisartan 40 mg versus losartan 50 mg on diastolic and
systolic blood pressure reduction showed a greater and signiﬁ-
cant effect for telmisartan. Indirect comparisons showed a
greater and signiﬁcant effect in both trough DBP/SBP versus all
other AIIA except candesartan where no signiﬁcant difference
was obtained. In particular, telmisartan 40 mg reduced 24-h DBP
by 7.3  0.7 compared to: valsartan 80 mg 4.7  5.7 (95% CI
between tx diff: -4.33, -0.80); irbesartan 150 mg 5.2  6.7
(95% CI between tx diff: -4.23, -0,003); losartan 50 mg
4.2  5.5 (95%CI between tx diff: -5.09, -1.10); candesartan
8 mg 5.8  8.0 (95% CI between tx diff: -3.99, 1.14). Similarly,
when comparing higher doses of the drugs, telmisartan 80 mg
results in greater and signiﬁcant reductions in both trough DBP
and SBP than losartan 100 mg and valsartan 160 mg, as well as
with irbesartan 300 mg and candesartan 16 mg but with no
statistical signiﬁcance. CONCLUSION: Overall, in the mono-
therapy studies both low and high dose telmisartan has an advan-
tage in reducing blood pressure over the other drugs of the class.
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EPROSARTANVERSUS OTHER ANGIOTENSIN-RECEPTOR
BLOCKERS COMMONLY USED IN POLAND (IRBESARTAN,
LOSARTAN,TELMISARTAN ANDVALSARTAN) IN PATIENTS
WITH HYPERTENSION-DIRECT ANALYSIS
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OBJECTIVES: To compare the clinical effectiveness of eprosar-
tan and irbesartan, losartan, telmisartan and valsartan in patients
with hypertension. METHODS: The clinical effectiveness analy-
sis in accordance with the Cochrane Collaboration guidelines
were performed. Only head-to head study with randomization
were include to analysis. RESULTS: Eprosartan vs losartan- One
RCT (head-to-head) was identify. There was no statistically sig-
niﬁcant difference between groups in change in systolic and dias-
tolic pressure. Also there was no statistically signiﬁcantly more
patients achieved clinical response after 4 weeks follow-up. The
incidence of adverse events were similar in both group. Eprosa-
rtan vs telmisartan- Analysis based on direct evidence (one RCT)
showed statistically important difference in change diastolic pres-
sure after 12 month, favors telmisartan: RD: 4 mmHG (95% CI:
3.51; 4.49). There was no statistically differences between com-
pared groups in change in systolic pressure. Frequency of adverse
events was also comparable between groups. Eprosartan vs val-
sartan or irbesartan: Because of lack of relevant study (head to
head), analysis could not be performed. CONCLUSION: Analy-
sis suggests that eprosartan has comparable efﬁcacy to losartan.
Telmisatran is more effective, compared with eprosartan, for
treatment of patients with hypertension. Safety of interventions
are similar.
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OBJECTIVES: To compare the efﬁcacy of rosuvastatin 40 mg
with 20 mg for treatment of hypercholesterolaemia and estimate
the associated impact on ﬁnal outcomes based on a meta-analysis
of 9 randomised controlled trials (RCTs) from the CRESTOR
clinical trial programme. METHODS: A regression analysis of
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mean LDL-C reduction and difference in event rate between
statin and placebo arms in published outcomes studies (4S,
CARE, LIPID, HPS), was performed for major clinical endpoints.
A model was developed to estimate LDL-C reductions using
alternative baseline LDL-C values and the weighted mean differ-
ence (WMD) from the meta-analysis. These were combined with
results from regression analyses to calculate percentage reduction
in cardiovascular events and impact estimated for a population
of 100,000. The model was also run using the 95% conﬁdence
intervals from the meta-analysis. RESULTS: Meta-analysis
demonstrated a signiﬁcant reduction in LDL-C in favour of rosu-
vastatin 40 mg (WMD –5.26%, 95% CI: –6.08% to –4.43%;
p < 0.00001). There was no signiﬁcant heterogeneity identiﬁed in
the meta-analysis (p = 0.42) with low inconsistency in trial
results (I2 = 2.1%). Regression analyses showed good correla-
tion (R2 > 0.65) between LDL-C reduction and percentage dif-
ference in event rates for coronary death, major coronary event,
non-fatal myocardial infarction (MI) and revascularisations
(CABG and PCTA). Simulations using alternative LDL-C distri-
butions with means varying from 3.40–7.56 mmol/L generated
LDL-C reductions of 1.68–3.78 and 1.85–4.18 for rosuvastatin
20 mg and 40 mg, respectively. These values translated into the
following reductions depending on the mean of the distribution:
0.33%–0.74% coronary deaths; 0.72%–1.62% major coronary
events; 0.52%–1.17% non-fatal MIs; 0.59%–1.32% revasculari-
sation procedures. Based on a population of 100,000, the incre-
mental beneﬁt of rosuvastatin 40 mg over 20 mg resulted in the
prevention of 329–742 coronary deaths, 721–1,624 major coro-
nary events, 517–1,165 non-fatal MIs and 586–1,321 revascu-
larisation procedures. CONCLUSION: Rosuvastatin 40 mg
reduces LDL-C signiﬁcantly more than 20 mg. Modelled out-
comes suggest this may translate into substantially fewer
cardiovascular-related events.
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OBJECTIVES: With the lowering of the recommended choles-
terol levels in Europe, use of lipid lowering drugs has become a
more important clinical option. The study aim was to determine
total cholesterol levels by type of lipid lowering therapy in the
primary care setting in France, Italy and the UK. METHODS:
The study populations were identiﬁed from the THALES
(France, Italy) and The Health Improvement Network “THIN”
(UK) primary care databases. Patients were included if they
received a ﬁbrate or statin prescription in the ﬁrst 6 months of
2005 (index), had a prescription at least 6 months before index
and had a valid cholesterol record during the 12 months after
index. To account for differing cholesterol reporting habits,
analyses were restricted to general practitioners with cholesterol
reporting rate >50%. Multivariate linear regression was applied
to compare the effect of drug type on cholesterol level by country.
RESULTS: The rates of statin use were 71%, 88% and 97% for
France, Italy and the UK respectively. In France, the median
cholesterol was 5.2 mmol/L among statin users (n = 22674;
mean age = 65; male = 57%) compared to 5.3 mmol/L among
ﬁbrate users (n = 9283; age = 66; male = 46%). In Italy,
the median cholesterol was 5.2 mmol/L among statin users
(n = 4822; age = 67; male = 48%) compared to 5.4 mmol/L
among ﬁbrates users (n = 641; age = 65; male = 56%). In the
UK, median cholesterol was 4.4 mmol/L among statin users
(n = 113252; age = 67; male = 55%) compared to 5.1 mmol/L
among ﬁbrate users (n = 3626; age = 65; male = 49%). For each
country, statin therapy was associated (p < 0.001) with lower
median cholesterol level after controlling for age, gender, dia-
betes and coronary heart disease. CONCLUSION: The use of
statins in primary care was dominant in all countries studied,
although prescribing habits varied. Cholesterol levels were lower
among statin users than ﬁbrate users and this difference was
greatest in the UK.
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WITH HYPERTENSION-INDIRECT ANALYSIS
Kaczor M,Wojcik R,Walczak J, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: To compare the clinical effectiveness of eprosa-
rtan and irbesartan, losartan, telmisartan and valsartan in
patients with hypertension. METHODS: The clinical effective-
ness analysis in accordance with the Cochrane Collaboration
guidelines were performed. In the absence (or lack of sufﬁcient
data) of RCT making head-to-head comparisons of eprosartan
vs other angiotensin-receptor blockers meta-analysis based on
an indirect comparison was performed, using placebo as the
common comparator (Bucher method). RESULTS: Eprosartan
vs losartan- Because of the lack of sufﬁcient data, indirect
analysis was performed. Compared drugs was comparable in
terms of efﬁcacy. In the safety analysis no signiﬁcant differences
were observed between groups except withdrawal due to
adverse events which was more common in losartan group OR
0.46 (95%CI: 0.23; 0.96). Eprosartan vs telmisartan- Indirect
analysis showed that there is now statistically signiﬁcantly dif-
ference in change systolic pressure. There was statistically sig-
niﬁcant difference between groups on favors telmisartan in
achieving clinical response OR 0.42 (95%CI: 0.23; 0.76).
Safety of both interventions was the same. Eprosartan vs val-
sartan or irbesartan: Analysis based on indirect evidence
showed no signiﬁcant differences between the groups in terms
of efﬁcacy (change in systolic and diastolic pressure, response
to treatment).The incidence of adverse events was similar in
compared groups. CONCLUSION: Analysis suggests that epro-
sartan has comparable efﬁcacy to losartan, valsartan, irbe-
sartan. Telmisartan is more effective compared with eprosartan
for treatment of patients with hypertension. Safety of interven-
tions is comparable. However, results based on indirect evi-
dence need to be viewed cautiously.
PCV9
DIFFERENT REDUCTIONS OF HOSPITALISATIONS FOR
CARDIOVASCULAR EVENTS AMONG 92035 USERS OF
STATINS IN A REAL LIFE SETTING
Heintjes EM1, Penning-van Beest FJA1, Johansson S2, Stalenhoef AF3,
Herings RMC1
1PHARMO Institute, Utrecht,The Netherlands, 2AstraZeneca R&D,
Mölndal, Sweden, 3Radboud University Medical Centre, Nijmegen,
Gelderland,The Netherlands
OBJECTIVES: This study compares the differences in incidences
of hospitalisations for cardiovascular events between users of
selected statins. METHODS: New statin users between January
1, 2000 and September 30, 2005 were extracted from the
PHARMO database (population 3 million) and followed for
maximally two years after start of statin use, up to December 31,
2005. Incidences of hospitalisations for fatal and non-fatal car-
diovascular disease (CVD) in general (including ischemic heart
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